Zoetis Inc.
A maker of medicines, vaccines, and diagnostics for animals, Zoetis sells well-known products like the dog itch-relief drugs Apoquel and Cytopoint and Simparica parasite preventives to veterinarians worldwide. Born in the 1950s as the animal health arm of Pfizer, it became a fully independent company in 2013. Its name comes from the Greek word "zoe," meaning life—a fitting nod to its mission of keeping animals healthy.
Granted 245.6K · Sold 106.9K
Granted 60.2K · Sold 32.4K
Sold 10.0K
Granted 11.3K · Bought 3.0K
Granted 46.8K · Sold 28.8K
Granted 11.3K · Bought 2.0K
Granted 39.9K
Bought 6.7K
Granted 23.5K
Granted 11.3K · Sold 4.5K
Granted 53.0K · Sold 48.7K
Granted 24.8K · Sold 10.5K
Granted 21.5K
Granted 11.3K · Sold 4.4K
Granted 9.7K
Granted 3.1K
Granted 10.3K
Granted 7.0K
Granted 12.9K · Sold 5.8K
Granted 4.6K
Granted 5.8K
Granted 3.1K
Granted 3.7K
Granted 3.8K
Granted 2.8K
Granted 1.6K
Granted 454
Granted 1.5K
Granted 895
Granted 1.3K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Peck Kristin CChief Executive Officer, Director · 58 transactions | — | 105.9K | 245.6K | — | 106.9K |
| David GlennExecutive Vice President · 9 transactions | +59.6% | 52.5Kas of Feb 2022 | 60.2K | — | 32.4K |
| Knupp Catherine A.Executive Vice President · 1 transaction | -18.6% | 43.6Kas of Nov 2021 | — | — | 10.0K |
| McCallister Michael BDirector · 18 transactions | — | 39.3K | 11.3K | 3.0K | — |
| Chen Heidi C.Executive Vice President · 19 transactions | +34.4% | 32.4Kas of Feb 2024 | 46.8K | — | 28.8K |
| Bisaro PaulDirector · 8 transactions | +91.8% | 27.9K | 11.3K | 2.0K | — |
| Joseph WettenyChief Financial Officer · 18 transactions | — | 22.8K | 39.9K | — | — |
| Damelio Frank ADirector · 1 transaction | +44.9% | 21.5K | — | 6.7K | — |
| Parent Louise MDirector · 16 transactions | +97.1% | 18.2K | 23.5K | — | — |
| Norden GregoryDirector · 20 transactions | — | 18.2K | 11.3K | — | 4.5K |
| Lagano RoxanneExecutive Vice President · 63 transactions | — | 16.5K | 53.0K | — | 48.7K |
| Trawicki RomanExecutive Vice President · 8 transactions | +149.4% | 14.2Kas of Mar 2022 | 24.8K | — | 10.5K |
| Scully Robert WDirector · 7 transactions | -27.7% | 13.1Kas of May 2025 | 21.5K | — | — |
| Reed Willie MDirector · 10 transactions | +115.7% | 12.9K | 11.3K | — | 4.4K |
| Rhodes LindaDirector · 10 transactions | +222.8% | 11.7Kas of May 2024 | 9.7K | — | — |
| Driscoll RimmaExecutive Vice President · 22 transactions | — | 5.9K | 3.1K | — | — |
| Mamilli WafaaExecutive Vice President · 10 transactions | — | 5.7Kas of Feb 2024 | 10.3K | — | — |
| Leatherberry Antoinette ReneeDirector · 10 transactions | — | 5.3K | 7.0K | — | — |
| Polzer Robert JExecutive Vice President · 27 transactions | — | 5.2Kas of Feb 2025 | 12.9K | — | 5.8K |
| Brannan JamieExecutive Vice President · 22 transactions | — | 4.3K | 4.6K | — | — |
| Broadhurst VanessaDirector · 8 transactions | — | 3.9K | 5.8K | — | — |
| Hattersley GavinDirector · 3 transactions | — | 3.4K | 3.1K | — | — |
| Sarbaugh KeithExecutive Vice President · 10 transactions | — | 3.3K | 3.7K | — | — |
| Ashton NicholasExecutive Vice President · 20 transactions | — | 2.2K | 3.8K | — | — |
| Ferran Astorga JeannetteExecutive Vice President · 20 transactions | — | 1.9K | 2.8K | — | — |
| Stetter MarkDirector · 1 transaction | — | 1.6K | 1.6K | — | — |
| Esch KevinExecutive Vice President · 8 transactions | — | 1.1K | 454 | — | — |
| Fuller JulieExecutive Vice President · 4 transactions | — | 1.1K | 1.5K | — | — |
| Banque Soria EsterExecutive Vice President · 2 transactions | — | 895as of Jul 2024 | 895 | — | — |
| Nayak Abhay UExecutive Vice President · 4 transactions | -100% | 0 | 1.3K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -240.3K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.